IMMUTEP

🇫🇷France

Country: 🇫🇷France

Ownership: -

Established: 2001-01-01

Employees: -

Market Cap: $363.8M

Website: http://www.immutep.com/

Clinical Trials

Study of Eftilagimod Alfa (Efti) in Combination with Pembrolizumab and Chemotherapy Versus Placebo in Combination with Pembrolizumab and Chemotherapy in Participants with Metastatic Non-Small Cell Lung Cancer (NSCLC) (TACTI-004)

Phase 3

Not yet recruiting

Conditions: Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)

Interventions: Biological: eftilagimod alfa
Drug: carboplatin plus paclitaxel
Drug: cisplatin or carboplatin + pemetrexed
Biological: Pembrolizumab (KEYTRUDA®)
Other: Placebo

First Posted Date: 2024-12-10

Last Posted Date: 2024-12-10

Lead Sponsor: Immutep S.A.S.

Target Recruit Count: 756

Registration Number: NCT06726265

A First-in-human Study of the Safety of an Immunosuppressive Antibody (IMP761) in Healthy Volunteers

Phase 1

Recruiting

Conditions: Healthy

Interventions: Drug: IMP761
Drug: Placebo

First Posted Date: 2024-10-15

Last Posted Date: 2024-10-15

Lead Sponsor: Immutep S.A.S.

Target Recruit Count: 49

Registration Number: NCT06637865

Locations: 🇳🇱
CHDR, Leiden, Netherlands

Study in Metastatic Breast Cancer Patients Receiving Eftilagimod Alpha or Placebo in Combination with Paclitaxel Chemotherapy

Phase 2

Active, not recruiting

Conditions: Breast Carcinoma

Interventions: Biological: eftilagimod alpha
Drug: Paclitaxel
Other: placebo

First Posted Date: 2023-02-28

Last Posted Date: 2024-12-17

Lead Sponsor: Immutep S.A.S.

Target Recruit Count: 849

Registration Number: NCT05747794

Locations: 🇺🇸
The Oncology Institute, Whittier, California, United States
🇺🇸
The George Washington University Cancer Center, Washington, D.C., District of Columbia, United States
🇺🇸
Carolina Blood and Cancer Care Associates, Rock Hill, South Carolina, United States

and more 19 locations

Combination Study With Eftilagimod Alpha (a Soluble LAG-3 Fusion Protein) and Pembrolizumab in Patients With Recurrent or Metastatic HNSCC

Phase 2

Active, not recruiting

Conditions: HNSCC

Interventions: Drug: eftilagimod alpha
Drug: pembrolizumab (KEYTRUDA®)

First Posted Date: 2021-03-23

Last Posted Date: 2024-10-31

Lead Sponsor: Immutep S.A.S.

Target Recruit Count: 171

Registration Number: NCT04811027

Locations: 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
🇺🇸
University of Alabama at Birmingham (UAB) - O'Neal Cancer Center, Birmingham, Alabama, United States
🇺🇸
Oncology Consultants, Houston, Texas, United States

and more 26 locations

A Study in Hormone Receptor-positive Metastatic Breast Carcinoma Patients to Test a New Schedule of Efti (IMP321, Eftilagimod Alpha) as Adjunctive to a Weekly Treatment Regimen of Paclitaxel

Phase 1

Withdrawn

Conditions: Metastatic Breast Cancer

Interventions: Drug: Eftilagimod Alpha
Drug: Paclitaxel

First Posted Date: 2020-02-05

Last Posted Date: 2023-03-22

Lead Sponsor: Immutep S.A.S.

Registration Number: NCT04252768

Combination Study With Soluble LAG-3 Fusion Protein Eftilagimod Alpha (IMP321) and Pembrolizumab in Patients With Previously Untreated Unresectable or Metastatic NSCLC, or Recurrent PD-X Refractory NSCLC or With Recurrent or Metastatic HNSCC

Phase 2

Completed

Conditions: NSCLC
HNSCC

Interventions: Drug: eftilagimod alpha
Drug: pembrolizumab (KEYTRUDA®)

First Posted Date: 2018-08-10

Last Posted Date: 2024-12-18

Lead Sponsor: Immutep S.A.S.

Target Recruit Count: 187

Registration Number: NCT03625323

Locations: 🇺🇸
Oncology Consultants, Houston, Texas, United States

IMP321 (Eftilagimod Alpha) as Adjunctive to a Standard Chemotherapy Paclitaxel Metastatic Breast Carcinoma

Phase 2

Completed

Conditions: Adenocarcinoma Breast Stage IV

Interventions: Biological: IMP321 (eftilagimod alpha)
Drug: Placebo
Drug: Paclitaxel

First Posted Date: 2015-11-25

Last Posted Date: 2021-10-05

Lead Sponsor: Immutep S.A.S.

Target Recruit Count: 242

Registration Number: NCT02614833

Locations: 🇧🇪
UZ Leuven, campus Gasthuisberg Department of General Medical Oncology and Multidisciplinary Breast Centre, Leuven, Belgium
🇩🇪
Onkologische Gemeinschaftspraxis am Bethanien-Krankenhaus Centrum für Hämatologie und Onkologie, Frankfurt, Germany
🇧🇪
Universitair Ziekenhuis Antwerpen Breast and Gynecological Oncology Unit, Edegem, Belgium

and more 26 locations

A Randomized Phase I Study of a Hepatitis B Antigen Combined With IMP321

Phase 1

Completed

Conditions: Healthy

Interventions: Biological: hepatitis B antigen (without alum) plus IMP321
Biological: hepatitis B antigen alone (without alum)
Biological: Engerix B

First Posted Date: 2006-07-20

Last Posted Date: 2008-04-25

Lead Sponsor: Immutep S.A.S.

Target Recruit Count: 48

Registration Number: NCT00354861

Locations: 🇫🇷
SGS Aster-Cephac, Paris, France

Phase I Study of IMP321 Given Alone or as an Adjuvant to a Reference Flu Antigen

Phase 1

Completed

Conditions: Healthy

Interventions: Biological: saline
Biological: IMP321

First Posted Date: 2006-07-20

Last Posted Date: 2008-04-24

Lead Sponsor: Immutep S.A.S.

Target Recruit Count: 60

Registration Number: NCT00354263

Locations: 🇫🇷
SGS Aster-Cephac, Paris, France

IMP321 Phase 1 Trial in Metastatic Renal Cell Carcinoma (MRCC)

Phase 1

Completed

Conditions: Stage IV Renal Cell Carcinoma

First Posted Date: 2006-07-13

Last Posted Date: 2010-01-07

Lead Sponsor: Immutep S.A.S.

Target Recruit Count: 24

Registration Number: NCT00351949

Locations: 🇫🇷
Institut Gustave Roussy, Villejuif, France

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy